Abivax has presented new preclinical and clinical data for obefazimod [...]

Long-term VIVID-2 data show more than 90% of patients with [...]

Amorphical has announced positive final long-term results from its Phase [...]

The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]

Amorphical, developer of nano-amorphous mineral-based pharmacologic agents, has announced positive [...]

Amorphical has appointed Eden Ben as chief executive officer, as [...]

Mirikizumab is now recommended by NICE for routine NHS use [...]

The National Institute for Health and Care Excellence (NICE) has [...]

A new collaboration aims to tackle the toughest challenges in [...]